Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
- 5 November 1998
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 339 (19), 1349-1357
- https://doi.org/10.1056/nejm199811053391902
Abstract
In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain.Keywords
This publication has 15 references indexed in Scilit:
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsThe New England Journal of Medicine, 1996
- Task force 8. Organization of preventive cardiology serviceJournal of the American College of Cardiology, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaThe New England Journal of Medicine, 1995
- Range of serum cholesterol values in the population developing coronary artery diseaseThe American Journal of Cardiology, 1995
- Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectorisThe American Journal of Cardiology, 1995
- Unstable angina: Pathogenesis, diagnosis, and treatmentCurrent Problems in Cardiology, 1993
- Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.BMJ, 1991
- The Value of Lowering Cholesterol after Myocardial InfarctionThe New England Journal of Medicine, 1990
- Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.BMJ, 1990
- Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)JAMA, 1986